Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Camrelizumab in
combination with platinum doublet neoadjuvant chemotherapy before surgery [neoadjuvant
phase], followed by Camrelizumab alone after surgery [adjuvant phase] in participants with
unresectable stage III non-small cell lung cancer.